Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... will be a poster summarizing results of a Phase 1 study of FOLOTYN in combination with gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies, and an oral ...
2009 NOV 16 ... with Xeloda® (capecitabine), Taxotere® (docetaxel) and Gemzar® (gemcitabine), respectively. ARRY-380 - ErbB2 selective inhibitor for cancer: Patient recruitment in ...
2009 NOV 9 ... "This study evaluates the efficacy of combining proton irradiation with gemcitabine, and the role the inhibitor of apoptosis proteins survivin and X-linked inhibitor of ...
2009 NOV 23 ... on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine and developed HFS again, which was controlled with aggressive skin care and ...
2009 NOV 9 ... Republic of China conducted a study "To optimize formulation methods for loading gemcitabine (GEM), the main drug against pancreatic cancer, into albumin nanoparticles for extended ...
2009 NOV 9 ... arm); vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC); gemcitabine 1,000 mg/m2 day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC); or topotecan 0.75 ...
2009 NOV 9 ... According to recent research from the United States, "Gemcitabine plus capecitabine has moderate efficacy in patients with advanced renal cell cancer ...
2009 NOV 2 ... toxicities (DLTs) and the maximum tolerated doses (MTDs) of the paclitaxel, gemcitabine, oxaliplatin combination administered biweekly in patients with advanced solid tumors. ...
2009 NOV 9 ... proliferation, cell cycle arrest, induction of apoptosis, combinatorial effects with gemcitabine, and effects on target protein levels were studied." "Low nanomolar ...
2009 NOV 23 ... New research, 'Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after ...
2009 NOV 16 ... of HER3 mRNA have been shown to associate with pertuzumab response when combined with gemcitabine," scientists in Scotland report. "We sought to define how pertuzumab ...
2009 NOV 2 ... including dacetuzumab in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for relapsed and refractory diffuse large B-cell lymphoma and dacetuzumab in ...
2009 NOV 23 ... Scientists discuss in 'Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent' new findings in acinar cell cancer. "Pancreatic acinar cell ...
2009 NOV 9 ... were established from a pancreatic cancer cell line and exposed in vitro to gamma-ray or gemcitabine to investigate the relevance of REG4 to the resistance to chemotherapy or radiotherapy. ...
2009 NOV 16 ... "A total of 387 chemotherapy-naive patients who received chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin) in a randomised controlled trial ...
2009 NOV 2 ... report. "While most patients in the target population are receiving either gemcitabine or 5-fluorouracil chemotherapy, the combination with CRAd has not yet been studied. This ...
2009 NOV 16 ... O-6-benzyl guanine (O(6)BG), at an optimal biological dose alone or in combination with gemcitabine inhibits human pancreatic cancer cell growth. Human pancreatic cancer L3.6pl and PANC1 ...
2009 NOV 9 ... the tumor for both docetaxel and cisplatin. The doublet combinations of cisplatin with gemcitabine and cisplatin with docetaxel showed gene expression signatures incorporating resistance ...
2009 NOV 23 ... compound did not inhibit DNA synthesis and therefore does not resemble the clinical drug gemcitabine," wrote Y. Xia and colleagues. The researchers concluded: "It did, ...
